JP4675318B2 - N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス - Google Patents
N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス Download PDFInfo
- Publication number
- JP4675318B2 JP4675318B2 JP2006503471A JP2006503471A JP4675318B2 JP 4675318 B2 JP4675318 B2 JP 4675318B2 JP 2006503471 A JP2006503471 A JP 2006503471A JP 2006503471 A JP2006503471 A JP 2006503471A JP 4675318 B2 JP4675318 B2 JP 4675318B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- hydrocarbon
- compound
- alkali metal
- hydrocarbon chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 115
- 230000008569 process Effects 0.000 title claims description 102
- 238000002360 preparation method Methods 0.000 title description 7
- 125000005216 haloheteroaryl group Chemical group 0.000 title 1
- -1 diarylamine compound Chemical class 0.000 claims description 91
- 239000003054 catalyst Substances 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003624 transition metals Chemical class 0.000 claims description 37
- 229910052783 alkali metal Inorganic materials 0.000 claims description 36
- 229910052723 transition metal Inorganic materials 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 229920006395 saturated elastomer Polymers 0.000 claims description 28
- 229930195733 hydrocarbon Natural products 0.000 claims description 27
- 239000004215 Carbon black (E152) Substances 0.000 claims description 23
- 239000002585 base Substances 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 21
- 150000002430 hydrocarbons Chemical group 0.000 claims description 20
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 17
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052763 palladium Inorganic materials 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 6
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical class [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 5
- NCMHKCKGHRPLCM-UHFFFAOYSA-N caesium(1+) Chemical class [Cs+] NCMHKCKGHRPLCM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 claims description 4
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical compound [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 229910001419 rubidium ion Inorganic materials 0.000 claims description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 3
- 150000001345 alkine derivatives Chemical class 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 6
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 3
- 235000010290 biphenyl Nutrition 0.000 claims 3
- 239000004305 biphenyl Substances 0.000 claims 3
- 125000006267 biphenyl group Chemical group 0.000 claims 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 3
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 claims 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 125000001931 aliphatic group Chemical group 0.000 description 43
- 239000002904 solvent Substances 0.000 description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 125000005266 diarylamine group Chemical group 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 11
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- 150000004982 aromatic amines Chemical class 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000003880 polar aprotic solvent Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- PIOZZBNFRIZETM-UHFFFAOYSA-L magnesium;2-carbonoperoxoylbenzoic acid;2-oxidooxycarbonylbenzoate Chemical compound [Mg+2].OOC(=O)C1=CC=CC=C1C([O-])=O.OOC(=O)C1=CC=CC=C1C([O-])=O PIOZZBNFRIZETM-UHFFFAOYSA-L 0.000 description 4
- BOPGURALGGUNMA-UHFFFAOYSA-N methyl 6-chloro-2-(4-fluorophenyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1C1=CC=C(F)C=C1 BOPGURALGGUNMA-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QBRORDIPGULCFR-UHFFFAOYSA-N tert-butyl n-(2,6-difluorophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=C(F)C=CC=C1F QBRORDIPGULCFR-UHFFFAOYSA-N 0.000 description 4
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 3
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000001118 alkylidene group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- YRABKXXUWVHIQT-UHFFFAOYSA-N ethyl 6-(2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxylate Chemical compound N1=C(C=2C(=CC(F)=CC=2)F)C(C(=O)OCC)=CC=C1NC1=C(F)C=CC=C1F YRABKXXUWVHIQT-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
- 229960005235 piperonyl butoxide Drugs 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- MEJLZECGRCKABL-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-1-[6-(4-fluorophenyl)-5-(hydroxymethyl)pyridin-2-yl]urea Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(CO)C=1C1=CC=C(F)C=C1 MEJLZECGRCKABL-UHFFFAOYSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101000976900 Homo sapiens Mitogen-activated protein kinase 14 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PFDXXDVNGTVHRK-UHFFFAOYSA-N [6-(n-carbamoyl-2,6-difluoroanilino)-2-(4-fluorophenyl)pyridin-3-yl]methyl n-(2-hydroxyethyl)carbamate Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C(N=1)=CC=C(COC(=O)NCCO)C=1C1=CC=C(F)C=C1 PFDXXDVNGTVHRK-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- JPJLYIZLSBBOKF-UHFFFAOYSA-N ethyl 6-chloro-2-(2,4-difluorophenyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1C1=CC=C(F)C=C1F JPJLYIZLSBBOKF-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- FRIQPFUXSNNBCW-UHFFFAOYSA-N methyl 2-(4-fluorophenyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1C1=CC=C(F)C=C1 FRIQPFUXSNNBCW-UHFFFAOYSA-N 0.000 description 2
- MYGAJZBZLONIBZ-UHFFFAOYSA-N methyl 2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1Cl MYGAJZBZLONIBZ-UHFFFAOYSA-N 0.000 description 2
- ZBTDXFBAJNFULF-UHFFFAOYSA-N methyl 6-(2,6-difluoroanilino)-2-(4-fluorophenyl)pyridine-3-carboxylate Chemical compound N1=C(C=2C=CC(F)=CC=2)C(C(=O)OC)=CC=C1NC1=C(F)C=CC=C1F ZBTDXFBAJNFULF-UHFFFAOYSA-N 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SLXQRAMAAPBUQJ-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid;magnesium;hexahydrate Chemical compound O.O.O.O.O.O.[Mg].OOC(=O)C1=CC=CC=C1C(O)=O SLXQRAMAAPBUQJ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- JHFQCANGPSTAQJ-UHFFFAOYSA-N COCCOCCOC.COCCOCCOC.COCCOC Chemical compound COCCOCCOC.COCCOCCOC.COCCOC JHFQCANGPSTAQJ-UHFFFAOYSA-N 0.000 description 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 1
- 241000694440 Colpidium aqueous Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical class [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical class [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical group [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000012018 catalyst precursor Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- KWGDNRLPXGPVGH-UHFFFAOYSA-N chloro hypochlorite phosphorous acid Chemical compound O(Cl)Cl.P(O)(O)O KWGDNRLPXGPVGH-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- ILDJJTQWIZLGPO-UHFFFAOYSA-N ethyl 6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1 ILDJJTQWIZLGPO-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- RMEDXVIWDFLGES-UHFFFAOYSA-N methyl 6-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1 RMEDXVIWDFLGES-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000006902 nitrogenation reaction Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
Description
本発明は、ジアリールアミンおよびそのアナログの容易な合成のためのプロセスに関する。本発明のプロセスは、高収率かつ高純度でジアリールアミンを生成する。本発明はまた、本発明のプロセスにおいて有用な中間体に関する。本発明はまた、本発明のプロセスによって生成されたジアリールアミンに関する。
プロテインキナーゼは、細胞外シグナルに対する細胞の種々の応答に関与する。最近、マイトジェン活性化プロテインキナーゼ(MAPK)のファミリーが発見された。このファミリーのメンバーは、リン酸化によってその基質を活性するSer/Thrキナーゼである[B.Steinら,Ann.Rep.Med.Chem.,31,pp.289−98(1996)]。MAPKは、成長因子、サイトカイン、UV照射およびストレス誘発性因子を含む種々のシグナルによって、それ自身が活性化される。
一実施形態に従って、本発明は、過アリール化の問題を回避し、大規模調製に従うことができ、そして高収率を提供する、ジアリールアミンの容易な合成のためのプロセスを提供する。本発明はまた、スズ化合物のような有害な試薬の使用を回避する。具体的には、本発明は、窒素に対する適切な保護基を添加することによって、一級アリールアミンが一時的に「二級」となるプロセスを提供する。一旦形成された場合、この保護されたアニリン誘導体は、アリール脱離基とのアルカリ金属塩促進性架橋結合か、または遷移金属触媒性架橋結合を受けて、中間体を形成し、この中間体は、脱保護によって、ジアリールアミン基質を生成する。この生成物は、副産物がほとんどなく、そして高収率で生成される。
(発明の詳細な説明)
本発明は、先行技術の困難性および欠点を克服し、そして式(I)の化合物:
ここで:
Ar1およびAr2は、独立にQであり;
ここで、各Qは、一以上の環原子において、0〜4個のヘテロ原子を有する飽和または不飽和の5〜8員環に必要に応じて縮合された、アリール環系またはヘテロアリール環系であり;
ここで、Qは、ハロ;C1〜C6脂肪族(必要に応じて、N(R’)2、OR’、CO2R’、C(O)N(R’)2、OC(O)N(R’)2、NR’CO2R’、NR’C(O)R’、SO2N(R’)2、N=CH−N(R’)2もしくはOPO3H2で置換される);C1〜C6アルコキシ(必要に応じて、N(R’)2、OR’、CO2R’、C(O)N(R’)2、OC(O)N(R’)2、SO2N(R’)2、NR’CO2R’、NR’C(O)R’、N=CH−N(R’)2、もしくはOPO3H2で置換される);Ar3;CF3;OCF3;OR’;SR’;SO2N(R’)2;OSO2R’;SCF3;NO2;CN;N(R’)2;CO2R’;CO2N(R’)2;C(O)N(R’)2;NR’C(O)R’;NR’CO2R’;NR’C(O)C(O)R’;NR’SO2R’;OC(O)R’;NR’C(O)R;NR’CO2R2;NR’C(O)C(O)R2;NR’C(O)N(R’)2;OC(O)N(R’)2;NR’SO2R2;NR’R;N(R)2;OC(O)R2;OPO3H2;およびN=CH−N(R’)2から独立に選択される一以上の置換基によって、必要に応じて置換され;
R’は、水素;C1〜C6脂肪族;または、ハロ、C1〜C6アルコキシ、シアノ、ニトロ、アミノ、ヒドロキシ、およびC1〜C6脂肪族より選択される1〜3個の置換基によって必要に応じて置換された5〜6員の環状炭素系もしくは複素環式環系から選択され;
R2は、以下:N(R’)2、OR’、CO2R’、C(O)N(R’)2もしくはSO2N(R’)2によって必要に応じて置換されたC1〜C6脂肪族;または以下:N(R’)2、OR’、CO2R’、C(O)N(R’)2もしくはSO2N(R’)2によって必要に応じて置換された炭素環式環系もしくは複素環式環系であり;
ここで、Ar3は、0〜4個のヘテロ原子を有する飽和または不飽和の5〜8員環に必要に応じて縮合されたアリール環系またはヘテロアリール環系であり;
ここで、Ar3は、以下:ハロ;C1〜C6脂肪族(必要に応じて、N(R’)2、OR’、CO2R’、C(O)N(R’)2、OC(O)N(R’)2、NR’CO2R、NR’C(O)R’、SO2N(R’)2、N=CH−N(R’)2、もしくはOPO3H2で置換される);C1〜C6アルコキシ(必要に応じて、N(R’)2、OR’、CO2R’、C(O)N(R’)2、OC(O)N(R’)2、SO2N(R’)2、NR’CO2R’、NR’C(O)R’、N=CH−N(R’)2、もしくはOPO3H2で置換される);CF3;OCF3;OR’;SR’;SO2N(R’)2;OSO2R’;SCF3;NO2;CN;N(R’)2;CO2R’;CO2N(R’)2;C(O)N(R’)2;NR’C(O)R’;NR’CO2R’;NR’C(O)C(O)R’;NR’SO2R’;OC(O)R’;NR’C(O)R2;NR’CO2R;NR’C(O)C(O)R2;NR’C(O)N(R’)2;OC(O)N(R’)2;NR’SO2R2;NR’R2;N(R2)2;OC(O)R2;OPO3H2;およびN=CH−N(R’)2から独立に選択される一以上の置換基によって、一以上の環原子において、必要に応じて置換される。
Xは、脱離基であり;そして、
Yは、−C(O)−O−Zであり;そして、
Zは、C1〜C6脂肪族、ベンジル、Fmoc、−SO2R’およびQから選択され、ただし、Qは、Xまたはアルキンでは置換されず;ここで、Ar1、Ar2、QおよびR’は、上記の通りである。
式(II)の化合物(適切な脱離基Xを有する)は、Y−NH−部分を有する式(III)の化合物と反応する。この反応は、アルカリ金属塩(例えば、炭酸セシウム)の存在下;または、代わりに遷移金属触媒ならびに必要に応じて塩基および一以上のリガンドの存在下で行われる。
工程2において、(IV)のラジカルYが除去されて、式(I)のジアリールアミンが生成される。
本発明に適切な遷移金属触媒は、遷移金属原子もしくは遷移金属イオン、および一以上のリガンドを含む。この遷移金属は、0価〜遷移金属が利用可能な任意のより高い原子価の範囲に及ぶ、任意の適切な酸化状態で存在し得る。好ましい実施形態に従い、この遷移金属触媒は、8族金属を含む。より好ましくは、この遷移金属触媒は、パラジウムを含む。触媒錯体はとしては、キレート性リガンドとしては、ホスフィンおよびビホスフィン、イミン、アルシンならびにこれらのハイブリッドのアルキル誘導体ならびにアリール誘導体が挙げられ得るが、それらに限定されない。
好ましい実施形態に従って、保護基除去工程(工程2)は、酸の存在下で起こる。適切な酸の例としては、HCl、HBr、HI、および有機酸(蟻酸、酢酸、プロピオン酸、ブタン酸、メタンスルホン酸、p−トルエンスルホン酸、ベンゼンスルホン酸、およびトリフルオロ酢酸を含む)が挙げられるが、これらに限定されない。本発明の好ましい酸としては、HCl、HBr、HI、およびTFAが挙げられる。
Boc=t−ブトキシカルボニル
Fmoc=フルオレニルメトキシカルボニル
Tf=トリフルオロメタンスルホネート
Ts=p−トルエンスルホニル
Ms=メタンスルホニル
TFA=トリフルオロ酢酸
Ac=アセチル
dba=トランス,トランス−ジベンジリデンアセトン
dppe=1,2−ビス−(ジフェニルホスフィノ)エタン
dppf=1,1’−ビス−(ジフェニルホスファニル)フェロセン
dppp=プロパン−1,3−ジイルビス(ジフェニルホスファン)
BINAP=2,2’−ビス(ジフェニルホスファニル)−1,1’−ビナフチル
MTBE=メチルt−ブチルエーテル
DME=ジメトキシエタン
CDI=1,1’−カルボニル−ジイミダゾール
DCC=N,N’−ジシクロヘキシルカルボジイミド
EDC=1−エチル−3−(3−ジメチルアミノプロピル)カルボジイミドヒドロクロリド
HOBt=N−ヒドロキシベンゾトリアゾール
NMP=N−メチルピロリジノン
DMF=ジメチルホルムアミド
MCPBA=m−クロロ過安息香酸
MMPP=モノ過酸化フタル酸マグネシウム六水和物
DIBAL−H=ジイソブチル水素化アルミニウム
LAH=水素化アルミニウムリチウム
過水素化物=トリエチル水素化ホウ素リチウム
L−セレクトリド=トリ−sec−ブチル水素化ホウ素リチウム
Red−Al=ビス(メトキシエトキシ)水素化アルミニウムナトリウム
IPA=イソプロパノール
グリム(glyme)=ジメトキシエタン
ジグリム(diglyme)=ビス(2−メトキシエチル)エーテル。
単独または「アラルキル」、「アラルコキシ」、または「アリールオキシアルキル」におけるように、より大きな部分の一部として用いられる用語「アリール」とは、全部で5員〜14員を有する単環式、二環式、および三環式の炭素環式環系をいう。ここで、この系における少なくとも一つの環は、芳香族であり、そしてこの系の各環は、3〜8個の環員を含む。用語「アリール」は、用語「アリール環」と相互交換可能に使用され得る。
R3は、C1〜6脂肪族;アリール;および、以下:C1〜6脂肪族、アリール、ニトロ、CN、CO2R’、CO2N(R’)2、OR’、NCO2R’、NR’C(O)N(R’)2、またはOC(O)N(R’)2で置換されたアリールから選択され;
ただし、R3は、t−ブチルではなく;
G1、G2、G3、G4、およびG5は、水素、脂肪族、アリール、置換アリール、ニトロ、CN、OR’、CO2R’、CO2N(R’)2、NR’CO2R’、NR’C(O)N(R’)2、OC(O)N(R’)2、F、Cl、Br、I、O−Ts、O−Ms、OSO2R’、およびOC(O)R’から独立に選択され;
Xは、脱離基であり;
Yは、−C(O)−O−Zであり;
Zは、C1〜6脂肪族、ベンジル、Fmoc、−SO2R’またはQから選択され、ただし、Qは、Xまたはアルキンで置換されておらず;
ここで、QおよびR’は、上記で定義されるものである。
Claims (46)
- 式:
該プロセスは、
(1)アルカリ金属塩または遷移金属触媒の存在下で、式21の化合物と式22のアミンとを結合させる工程:
(2)得られた化合物からラジカルYを酸の存在下で除去する工程、
を包含し、
ここで:
各Qは、0〜4個のヘテロ原子を有する飽和または不飽和の5〜8員環に必要に応じて縮合されたアリール環系またはヘテロアリール環系であり;
ここでQは、1つ以上の環原子において、ハロ;必要に応じて以下:
R’は、水素;C1〜C6 炭化水素鎖またはC 3 〜C 6 単環式炭化水素であって、該C 1 〜C 6 炭化水素鎖は、完全に飽和しているか、もしくは一以上の不飽和の単位を含有しており、該C 3 〜C 6 単環式炭化水素が、分子の残りに対して単一の結合点を有し、完全に飽和しているか、もしくは一以上の不飽和の単位を含有するが芳香族ではない、C 1 〜C 6 炭化水素鎖またはC 3 〜C 6 単環式炭化水素;または、ハロ、C1〜C6アルコキシ、シアノ、ニトロ、アミノ、ヒドロキシ、およびC1〜C6 炭化水素鎖またはC 3 〜C 6 単環式炭化水素から独立して選択される1〜3個の置換基で必要に応じて置換される5〜6員の炭素環式環系もしくは複素環式環系から選択され、該C 1 〜C 6 炭化水素鎖が、完全に飽和しているか、もしくは一以上の不飽和の単位を含有し、該C 3 〜C 6 単環式炭化水素が、分子の残りに対して単一の結合点を有し、完全に飽和しているか、もしくは一以上の不飽和の単位を含有するが芳香族ではなく;
R2は、必要に応じて以下:
ここでAr3は、0〜4個のヘテロ原子を有する飽和または不飽和の5〜8員環に必要に応じて縮合されたアリール環系またはヘテロアリール環系であり;
ここでAr3は、1つ以上の環原子において、ハロ;必要に応じて以下:
Xは、脱離基であり;
Yは、−C(O)−O−Zであり;そして
Zは、C1〜C6 炭化水素鎖またはC 3 〜C 6 単環式炭化水素、ベンジル、フルオレニルメトキシカルボニル、−SO2R’またはQであり、該C 1 〜C 6 炭化水素鎖は、完全に飽和しているか、もしくは一以上の不飽和の単位を含有し、該C 3 〜C 6 単環式炭化水素が、分子の残りに対して単一の結合点を有し、完全に飽和しているか、もしくは一以上の不飽和の単位を含有するが芳香族ではなく、ただし、Qは、Xまたはアルキンで置換されず、
R 3 は、炭化水素鎖またはC 3 〜C 6 単環式炭化水素であって、該炭化水素鎖は、完全に飽和しているか、もしくは一以上の不飽和の単位を含有し、該C 3 〜C 6 単環式炭化水素が、分子の残りに対して単一の結合点を有し、完全に飽和しているか、もしくは一以上の不飽和の単位を含有するが芳香族ではない炭化水素鎖またはC 3 〜C 6 単環式炭化水素、アリール、または、以下:炭化水素鎖またはC 3 〜C 6 単環式炭化水素であって、該炭化水素鎖は、完全に飽和しているか、もしくは一以上の不飽和の単位を含有し、該C 3 〜C 6 単環式炭化水素が、分子の残りに対して単一の結合点を有し、完全に飽和しているか、もしくは一以上の不飽和の単位を含有するが芳香族ではない炭化水素鎖またはC 3 〜C 6 単環式炭化水素、アリール、ニトロ、
ただし、R 3 はt−ブチルではなく;そして
G 1 、G 2 、G 3 、G 4 、およびG 5 は、独立して、水素、炭化水素鎖またはC 3 〜C 6 単環式炭化水素、アリール、置換アリール、ニトロ、
プロセス。 - 前記プロセスが、遷移金属触媒を使用して行われる、請求項1に記載のプロセス。
- 前記遷移金属触媒が、パラジウムを含む、請求項2に記載のプロセス。
- 請求項3に記載のプロセスであって、前記触媒がPdLnであり、ここで
各Lが、独立して、−OAc、−O−トリル、ハロゲン、トリフェニルホスフィン、1,2−ビス−(ジフェニルホスフィノ)エタン、1,1’−ビス−(ジフェニルホスファニル)フェロセン、トランス,トランス−ジベンジリデンアセトン、および2,2’−ビス(ジフェニルホスファニル)−1,1’−ビナフチルから選択され;そしてnが、0〜4の整数である、
プロセス。 - 式21の化合物と式22のアミンとを結合させる工程が、塩基の存在下で行われる、請求項2に記載のプロセス。
- 前記塩基が、KOtBu、NaOtBu、K3PO4、Na2CO3、およびCs2CO3から選択される、請求項5に記載のプロセス。
- 前記プロセスが、アルカリ金属塩を使用して行われる、請求項1に記載のプロセス。
- 前記アルカリ金属塩が、カリウムイオンの塩、ルビジウムイオンの塩、またはセシウムイオンの塩から選択される、請求項7に記載のプロセス。
- 前記アルカリ金属塩が、炭酸カリウムまたは炭酸セシウムから選択される、請求項8に記載のプロセス。
- 前記アルカリ金属塩が、炭酸セシウムである、請求項9に記載のプロセス。
- Xが、−Cl、−Br、−I、−F、−O−トリフルオロメタンスルホネート、−O−p−トルエンスルホニル、ヨードニウム、およびジアゾからなる群より選択される、請求項1に記載のプロセス。
- Yがt−ブトキシカルボニルである、請求項1に記載のプロセス。
- 前記プロセスが、遷移金属触媒を使用して行われる、請求項13に記載のプロセス。
- 前記遷移金属触媒が、パラジウムを含む、請求項14に記載のプロセス。
- 請求項15に記載のプロセスであって、前記触媒がPdLnであり、ここで
各Lが、独立して、−OAc、−O−トリル、ハロゲン、トリフェニルホスフィン、1,2−ビス−(ジフェニルホスフィノ)エタン、1,1’−ビス−(ジフェニルホスファニル)フェロセン、トランス,トランス−ジベンジリデンアセトン、および2,2’−ビス(ジフェニルホスファニル)−1,1’−ビナフチルから選択され;そしてnが、0〜4の整数である、
プロセス。 - 式41aの化合物と式42aのアミンとを結合させる工程が、塩基の存在下で行われる、請求項13に記載のプロセス。
- 前記塩基が、KOtBu、NaOtBu、K3PO4、Na2CO3、およびCs2CO3から選択される、請求項17に記載のプロセス。
- 前記プロセスが、アルカリ金属塩を使用して行われる、請求項13に記載のプロセス。
- 前記アルカリ金属塩が、カリウムイオンの塩、ルビジウムイオンの塩、またはセシウムイオンの塩から選択される、請求項19に記載のプロセス。
- 前記アルカリ金属塩が、炭酸カリウムまたは炭酸セシウムから選択される、請求項20に記載のプロセス。
- 前記アルカリ金属塩が、炭酸セシウムである、請求項21に記載のプロセス。
- Xが、−Cl、−Br、−I、−F、−O−トリフルオロメタンスルホネート、−O−p−トルエンスルホニル、ヨードニウム、およびジアゾからなる群より選択される、請求項13に記載のプロセス。
- Yがt−ブトキシカルボニルである、請求項13に記載のプロセス。
- 前記プロセスが、遷移金属触媒を使用して行われる、請求項25に記載のプロセス。
- 前記遷移金属触媒が、パラジウムを含む、請求項26に記載のプロセス。
- 請求項27に記載のプロセスであって、前記触媒がPdLnであり、ここで
各Lが、独立して、−OAc、−O−トリル、ハロゲン、トリフェニルホスフィン、1,2−ビス−(ジフェニルホスフィノ)エタン、1,1’−ビス−(ジフェニルホスファニル)フェロセン、トランス,トランス−ジベンジリデンアセトン、および2,2’−ビス(ジフェニルホスファニル)−1,1’−ビナフチルから選択され;そしてnが、0〜4の整数である、
プロセス。 - 式61aの化合物と式42aのアミンとを結合させる工程が、塩基の存在下で行われる、請求項25に記載のプロセス。
- 前記塩基が、KOtBu、NaOtBu、K3PO4、Na2CO3、およびCs2CO3から選択される、請求項29に記載のプロセス。
- 前記プロセスが、アルカリ金属塩を使用して行われる、請求項25に記載のプロセス。
- 前記アルカリ金属塩が、カリウムイオンの塩、ルビジウムイオンの塩、またはセシウムイオンの塩から選択される、請求項31に記載のプロセス。
- 前記アルカリ金属塩が、炭酸カリウムまたは炭酸セシウムから選択される、請求項32に記載のプロセス。
- 前記アルカリ金属塩が、炭酸セシウムである、請求項33に記載のプロセス。
- Xが、−Cl、−Br、−I、−F、−O−トリフルオロメタンスルホネート、−O−p−トルエンスルホニル、ヨードニウム、およびジアゾからなる群より選択される、請求項25に記載のプロセス。
- Yがt−ブトキシカルボニルである、請求項25に記載のプロセス。
- 前記プロセスが、炭酸セシウムを使用して行われる、請求項37に記載のプロセス。
- 工程(a)における前記塩基が、NaOHである、請求項39に記載のプロセス。
- 工程(b)における前記酸が、HClである、請求項39に記載のプロセス。
- 前記酸が、HCl、HBr、HI、および有機酸からなる群より選択される、請求項1に記載のプロセス。
- 前記酸が、HCl、HBr、HI、および有機酸からなる群より選択される、請求項13に記載のプロセス。
- 前記酸が、HCl、HBr、HI、および有機酸からなる群より選択される、請求項25に記載のプロセス。
- 前記酸が、HCl、HBr、HI、および有機酸からなる群より選択される、請求項37に記載のプロセス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44664103P | 2003-02-10 | 2003-02-10 | |
US47427203P | 2003-05-28 | 2003-05-28 | |
PCT/US2004/003933 WO2004072038A1 (en) | 2003-02-10 | 2004-02-10 | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010264372A Division JP2011037909A (ja) | 2003-02-10 | 2010-11-26 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
JP2010264371A Division JP2011037908A (ja) | 2003-02-10 | 2010-11-26 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006517235A JP2006517235A (ja) | 2006-07-20 |
JP2006517235A5 JP2006517235A5 (ja) | 2011-01-20 |
JP4675318B2 true JP4675318B2 (ja) | 2011-04-20 |
Family
ID=32871996
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006503471A Expired - Fee Related JP4675318B2 (ja) | 2003-02-10 | 2004-02-10 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
JP2010264372A Pending JP2011037909A (ja) | 2003-02-10 | 2010-11-26 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
JP2010264371A Pending JP2011037908A (ja) | 2003-02-10 | 2010-11-26 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
JP2014009078A Pending JP2014133745A (ja) | 2003-02-10 | 2014-01-22 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010264372A Pending JP2011037909A (ja) | 2003-02-10 | 2010-11-26 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
JP2010264371A Pending JP2011037908A (ja) | 2003-02-10 | 2010-11-26 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
JP2014009078A Pending JP2014133745A (ja) | 2003-02-10 | 2014-01-22 | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス |
Country Status (13)
Country | Link |
---|---|
US (3) | US7115746B2 (ja) |
EP (2) | EP2562158A1 (ja) |
JP (4) | JP4675318B2 (ja) |
KR (1) | KR20050101200A (ja) |
CN (1) | CN101723891A (ja) |
AU (1) | AU2004212494B2 (ja) |
CA (2) | CA2755297A1 (ja) |
HK (1) | HK1087117A1 (ja) |
MX (1) | MXPA05008450A (ja) |
NO (1) | NO20054201L (ja) |
NZ (1) | NZ542153A (ja) |
RU (1) | RU2351590C2 (ja) |
WO (1) | WO2004072038A1 (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004212494B2 (en) * | 2003-02-10 | 2011-03-17 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
EP1667992B1 (en) | 2003-09-19 | 2007-01-24 | Astrazeneca AB | Quinazoline derivatives |
JP2008540537A (ja) * | 2005-05-09 | 2008-11-20 | アキリオン ファーマシューティカルズ,インコーポレーテッド | チアゾール化合物および使用方法 |
JP2008545696A (ja) * | 2005-05-23 | 2008-12-18 | スミスクライン・ビーチャム・コーポレイション | 肥満の処置のためのp38markの阻害 |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
US20070225339A1 (en) * | 2006-03-07 | 2007-09-27 | Ramon Mohanlal | Compositions and methods for treating rheumatoid arthritis |
JP2009529059A (ja) * | 2006-03-08 | 2009-08-13 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 抗c型肝炎ウイルス活性を有する置換アミノチアゾール誘導体 |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
BRPI0811939A2 (pt) * | 2007-05-22 | 2014-11-25 | Achillion Pharmaceuticals Inc | Tiazóis substituídos por heteroarila |
CA2699718C (en) | 2007-09-21 | 2014-05-27 | Array Biopharma Inc. | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
MX364936B (es) | 2007-12-07 | 2019-05-15 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
AU2013205160B2 (en) * | 2007-12-07 | 2016-05-19 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
NZ585880A (en) | 2007-12-07 | 2012-08-31 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
KR101670089B1 (ko) * | 2008-03-18 | 2016-10-27 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 (pgi2) 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
US8106209B2 (en) * | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
BRPI0921369B8 (pt) | 2008-11-26 | 2021-05-25 | Arena Pharm Inc | composto modulador do receptor de prostaciclina (pgi2), sua composição, sua composição farmacêutica, seus usos, bem como processos para a preparação das referidas composições |
PT2370413E (pt) | 2008-12-08 | 2015-10-23 | Arena Pharm Inc | Moduladores do recetor da prostaciclina (pgi2) úteis para o tratamento de distúrbios relacionados com o mesmo |
EP2396302A2 (en) | 2009-02-13 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) |
CN102378756A (zh) | 2009-02-13 | 2012-03-14 | 沃泰克斯药物股份有限公司 | 2-(2,4-二氟苯基)-6-(1-(2,6-二氟苯基)脲基)烟酰胺的固体形式 |
JP5312570B2 (ja) * | 2009-02-27 | 2013-10-09 | 帝人ファーマ株式会社 | 遷移金属触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法 |
GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
EP3150198B1 (en) | 2010-04-07 | 2021-09-22 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
HUE030166T2 (en) * | 2010-08-27 | 2017-05-29 | Teijin Pharma Ltd | Process for the preparation of a phenyl-substituted heterocyclic derivative by coupling using a palladium compound |
DE102012003281B4 (de) | 2011-02-24 | 2014-02-13 | Tokai Rubber Industries, Ltd. | Berührungsschalter |
BR112016010403A2 (pt) | 2013-11-12 | 2017-08-08 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr |
RU2537848C1 (ru) * | 2013-12-10 | 2015-01-10 | Федеральное государственное казенное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации" | Способ получения 2-хлор-5-гидроксиметилпиридина |
KR102484589B1 (ko) | 2014-10-23 | 2023-01-04 | 아레나 파마슈티칼스, 인크. | Pgi2 수용체 관련 병태의 치료 방법 |
EP3221692B1 (en) | 2014-11-18 | 2021-06-23 | Vertex Pharmaceuticals Inc. | Process of conducting high throughput testing high performance liquid chromatography |
AU2018227842B2 (en) | 2017-03-01 | 2024-05-02 | Arena Pharmaceuticals, Inc. | Compositions comprising PGI2-receptor agonists and processes for the preparation thereof |
AU2018346709A1 (en) | 2017-10-05 | 2020-04-16 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of DUX4 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
TW202246233A (zh) | 2021-02-19 | 2022-12-01 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
AU2022222472A1 (en) | 2021-02-19 | 2023-09-28 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
KR20240149924A (ko) | 2022-02-15 | 2024-10-15 | 유나이티드 세러퓨틱스 코오포레이션 | 결정질 프로스타시클린 (ip) 수용체 효능제 및 그의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10512264A (ja) | 1995-01-12 | 1998-11-24 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
WO2000017175A1 (en) | 1998-09-18 | 2000-03-30 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
AU2001283237B2 (en) * | 2000-08-11 | 2007-09-20 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
US7217533B2 (en) * | 2001-06-21 | 2007-05-15 | Baylor College Of Medicine | P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target |
AU2004212494B2 (en) * | 2003-02-10 | 2011-03-17 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
-
2004
- 2004-02-10 AU AU2004212494A patent/AU2004212494B2/en not_active Ceased
- 2004-02-10 MX MXPA05008450A patent/MXPA05008450A/es active IP Right Grant
- 2004-02-10 CN CN200910252643A patent/CN101723891A/zh active Pending
- 2004-02-10 US US10/775,687 patent/US7115746B2/en not_active Expired - Fee Related
- 2004-02-10 CA CA2755297A patent/CA2755297A1/en not_active Abandoned
- 2004-02-10 KR KR1020057014640A patent/KR20050101200A/ko not_active Application Discontinuation
- 2004-02-10 NZ NZ542153A patent/NZ542153A/en unknown
- 2004-02-10 EP EP12193459A patent/EP2562158A1/en not_active Withdrawn
- 2004-02-10 JP JP2006503471A patent/JP4675318B2/ja not_active Expired - Fee Related
- 2004-02-10 RU RU2005128274/04A patent/RU2351590C2/ru not_active IP Right Cessation
- 2004-02-10 CA CA002515669A patent/CA2515669A1/en not_active Abandoned
- 2004-02-10 EP EP04709916A patent/EP1603878B1/en not_active Expired - Lifetime
- 2004-02-10 WO PCT/US2004/003933 patent/WO2004072038A1/en active Application Filing
-
2005
- 2005-09-09 NO NO20054201A patent/NO20054201L/no unknown
-
2006
- 2006-06-29 HK HK06107396.9A patent/HK1087117A1/xx not_active IP Right Cessation
- 2006-08-15 US US11/504,543 patent/US8034950B2/en not_active Expired - Fee Related
-
2010
- 2010-11-26 JP JP2010264372A patent/JP2011037909A/ja active Pending
- 2010-11-26 JP JP2010264371A patent/JP2011037908A/ja active Pending
-
2011
- 2011-08-24 US US13/216,530 patent/US8686157B2/en not_active Expired - Lifetime
-
2014
- 2014-01-22 JP JP2014009078A patent/JP2014133745A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2351590C2 (ru) | 2009-04-10 |
US20040230058A1 (en) | 2004-11-18 |
HK1087117A1 (en) | 2006-10-06 |
US20070173649A1 (en) | 2007-07-26 |
EP1603878B1 (en) | 2013-01-02 |
JP2011037908A (ja) | 2011-02-24 |
CA2755297A1 (en) | 2004-08-26 |
MXPA05008450A (es) | 2005-10-18 |
US8686157B2 (en) | 2014-04-01 |
NO20054201L (no) | 2005-10-06 |
US7115746B2 (en) | 2006-10-03 |
EP2562158A1 (en) | 2013-02-27 |
JP2006517235A (ja) | 2006-07-20 |
US20120157684A1 (en) | 2012-06-21 |
AU2004212494B2 (en) | 2011-03-17 |
KR20050101200A (ko) | 2005-10-20 |
RU2005128274A (ru) | 2006-01-27 |
EP1603878A1 (en) | 2005-12-14 |
AU2004212494A1 (en) | 2004-08-26 |
NZ542153A (en) | 2009-01-31 |
JP2011037909A (ja) | 2011-02-24 |
JP2014133745A (ja) | 2014-07-24 |
CA2515669A1 (en) | 2004-08-26 |
WO2004072038A1 (en) | 2004-08-26 |
NO20054201D0 (no) | 2005-09-09 |
US8034950B2 (en) | 2011-10-11 |
CN101723891A (zh) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4675318B2 (ja) | N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス | |
JP2006517235A5 (ja) | ||
JP5693239B2 (ja) | 4−ピリジノン化合物および癌についてのその使用 | |
TWI510451B (zh) | 具有hiv接合酶抑制活性的化合物之製造方法 | |
KR101312816B1 (ko) | 2-피리딜에틸카르복스아미드 유도체의 제조 방법 | |
RU2497808C2 (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов уротензина ii | |
ZA200506402B (en) | Process for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a haloheteroaryl and analogous process | |
US8461345B2 (en) | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) | |
KR0182266B1 (ko) | 아미노피리딘, 아닐린 및 피콜릴아민의 피콜릴셀레노벤즈아미드 | |
CZ294344B6 (cs) | Způsob výroby arylamidů heteroaromatických karboxylových kyselin | |
EP1611101A1 (en) | Substituted pyridines via boronic acid coupling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070208 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101025 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101101 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101227 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110125 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140204 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |